Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MDGL - US5588681057 - Common Stock

571.33 USD
+18.86 (+3.41%)
Last: 12/11/2025, 8:00:01 PM
572 USD
+0.67 (+0.12%)
Pre-Market: 12/12/2025, 4:04:47 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MDGL. MDGL was compared to 531 industry peers in the Biotechnology industry. While MDGL seems to be doing ok healthwise, there are quite some concerns on its profitability. MDGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MDGL has reported negative net income.
In the past year MDGL has reported a negative cash flow from operations.
MDGL had negative earnings in each of the past 5 years.
In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of MDGL (-21.22%) is better than 74.20% of its industry peers.
Looking at the Return On Equity, with a value of -46.21%, MDGL is in the better half of the industry, outperforming 67.42% of the companies in the same industry.
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

The Gross Margin of MDGL (95.25%) is better than 95.10% of its industry peers.
MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
MDGL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MDGL has more shares outstanding
The debt/assets ratio for MDGL has been reduced compared to a year ago.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 9.12 indicates that MDGL is not in any danger for bankruptcy at the moment.
MDGL has a better Altman-Z score (9.12) than 80.23% of its industry peers.
A Debt/Equity ratio of 0.54 indicates that MDGL is somewhat dependend on debt financing.
MDGL has a worse Debt to Equity ratio (0.54) than 72.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z 9.12
ROIC/WACCN/A
WACC8.73%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

MDGL has a Current Ratio of 3.44. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
MDGL's Current ratio of 3.44 is on the low side compared to the rest of the industry. MDGL is outperformed by 60.08% of its industry peers.
A Quick Ratio of 3.26 indicates that MDGL has no problem at all paying its short term obligations.
MDGL's Quick ratio of 3.26 is in line compared to the rest of the industry. MDGL outperforms 40.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.44
Quick Ratio 3.26
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.60% over the past year.
MDGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 864.21%.
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%

3.2 Future

MDGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.00% yearly.
The Revenue is expected to grow by 85.75% on average over the next years. This is a very strong growth
EPS Next Y54.07%
EPS Next 2Y46.04%
EPS Next 3Y43.78%
EPS Next 5Y34%
Revenue Next Year444.3%
Revenue Next 2Y188.74%
Revenue Next 3Y129.31%
Revenue Next 5Y85.75%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 -20 40 60

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDGL. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 194.66, MDGL can be considered very expensive at the moment.
MDGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDGL is cheaper than 87.76% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.96, MDGL is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 194.66
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDGL does not grow enough to justify the current Price/Earnings ratio.
MDGL's earnings are expected to grow with 43.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.04%
EPS Next 3Y43.78%

More info and screens

0

5. Dividend

5.1 Amount

MDGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (12/11/2025, 8:00:01 PM)

Premarket: 572 +0.67 (+0.12%)

571.33

+18.86 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners96.81%
Inst Owner Change2.02%
Ins Owners0.95%
Ins Owner Change2.36%
Market Cap12.97B
Revenue(TTM)740.64M
Net Income(TTM)-289.13M
Analysts83.48
Price Target573.11 (0.31%)
Short Float %18.03%
Short Ratio10.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.41%
Min EPS beat(2)-133.61%
Max EPS beat(2)48.79%
EPS beat(4)3
Avg EPS beat(4)-8.49%
Min EPS beat(4)-133.61%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)-2.09%
EPS beat(12)6
Avg EPS beat(12)-1.21%
EPS beat(16)8
Avg EPS beat(16)-1.44%
Revenue beat(2)2
Avg Revenue beat(2)21.21%
Min Revenue beat(2)13.88%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)15.85%
Min Revenue beat(4)2.78%
Max Revenue beat(4)28.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.42%
PT rev (3m)23.22%
EPS NQ rev (1m)83.21%
EPS NQ rev (3m)92.68%
EPS NY rev (1m)-6.15%
EPS NY rev (3m)4.8%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)11.99%
Revenue NY rev (1m)8.13%
Revenue NY rev (3m)8.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 194.66
P/S 17.52
P/FCF N/A
P/OCF N/A
P/B 20.74
P/tB 20.99
EV/EBITDA N/A
EPS(TTM)-12.89
EYN/A
EPS(NY)2.93
Fwd EY0.51%
FCF(TTM)-7.25
FCFYN/A
OCF(TTM)-7.07
OCFYN/A
SpS32.61
BVpS27.55
TBVpS27.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.25%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 274.34%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.44
Quick Ratio 3.26
Altman-Z 9.12
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
EPS Next Y54.07%
EPS Next 2Y46.04%
EPS Next 3Y43.78%
EPS Next 5Y34%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%
Revenue Next Year444.3%
Revenue Next 2Y188.74%
Revenue Next 3Y129.31%
Revenue Next 5Y85.75%
EBIT growth 1Y43.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.19%
EBIT Next 3Y41.27%
EBIT Next 5YN/A
FCF growth 1Y45.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.97%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / MDGL FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MDGL.


What is the valuation status of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a valuation rating of 2 / 10 to MADRIGAL PHARMACEUTICALS INC (MDGL). This can be considered as Overvalued.


Can you provide the profitability details for MADRIGAL PHARMACEUTICALS INC?

MADRIGAL PHARMACEUTICALS INC (MDGL) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for MDGL stock?

The Earnings per Share (EPS) of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 54.07% in the next year.